| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11253472 | BENUVIA | Oral cannabinoid formulations |
Aug, 2028
(4 years from now) | |
| US9345771 | BENUVIA | Oral cannabinoid formulations |
Aug, 2028
(4 years from now) | |
| US8222292 | BENUVIA | Liquid cannabinoid formulations |
Aug, 2028
(4 years from now) | |
| US10265293 | BENUVIA | Oral cannabinoid formulations |
Aug, 2028
(4 years from now) | |
Syndros is owned by Benuvia.
Syndros contains Dronabinol.
Syndros has a total of 4 drug patents out of which 0 drug patents have expired.
Syndros was authorised for market use on 23 March, 2017.
Syndros is available in solution;oral dosage forms.
The generics of Syndros are possible to be released after 06 August, 2028.
Drugs and Companies using DRONABINOL ingredient
Market Authorisation Date: 23 March, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
How can I launch a generic of SYNDROS before it's drug patent expiration?
More Information on Dosage
SYNDROS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic